Unknown

Dataset Information

0

FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.


ABSTRACT: The M2 subtype Acute Myeloid Leukemia (AML-M2) with t(8;21) represents an unmet challenge because of poor clinical outcomes in a sizable portion of patients. In this study,we report that FTY720 (Fingolimod), a sphingosine analogue and an FDA approved drug for treating of multiple sclerosis, shows antitumorigenic activity against the Kasumi-1 cell line, xenograft mouse models and leukemic blasts isolated from AML-M2 patients with t(8;21) translocation. Primary investigation indicated that FTY720 caused cell apoptosis through caspases and protein phosphatase 2A (PP2A) activation. Transcriptomic profiling further revealed that FTY720 treatment could upregulate AML1 target genes and interfere with genes involved in ceramide synthesis. Treatment with FTY720 led to the elimination of AML1-ETO oncoprotein and caused cell cycle arrest. More importantly, FTY720 treatment resulted in rapid and significant increase of pro-apoptotic ceramide levels, determined by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry based lipidomic approaches. Structural simulation model had also indicated that the direct binding of ceramide to inhibitor 2 of PP2A (I2PP2A) could reactivate PP2A and cause cell death. This study demonstrates, for the first time, that accumulation of ceramide plays a central role in FTY720 induced cell death of AML-M2 with t(8;21). Targeting sphingolipid metabolism by using FTY720 may provide novel insight for the drug development of treatment for AML-M2 leukemia.

SUBMITTER: Chen L 

PROVIDER: S-EPMC4106898 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.

Chen Limin L   Luo Liu-Fei LF   Lu Junyan J   Li Lianchun L   Liu Yuan-Fang YF   Wang Jiang J   Liu Hong H   Song Heng H   Jiang Hualiang H   Chen Sai-Juan SJ   Luo Cheng C   Li Keqin Kathy KK  

PloS one 20140722 7


The M2 subtype Acute Myeloid Leukemia (AML-M2) with t(8;21) represents an unmet challenge because of poor clinical outcomes in a sizable portion of patients. In this study,we report that FTY720 (Fingolimod), a sphingosine analogue and an FDA approved drug for treating of multiple sclerosis, shows antitumorigenic activity against the Kasumi-1 cell line, xenograft mouse models and leukemic blasts isolated from AML-M2 patients with t(8;21) translocation. Primary investigation indicated that FTY720  ...[more]

Similar Datasets

| S-EPMC7056541 | biostudies-literature
| S-EPMC6449485 | biostudies-literature
| S-EPMC6838108 | biostudies-literature
| S-EPMC6330064 | biostudies-literature
| S-EPMC6676407 | biostudies-literature
2003-10-09 | E-MEXP-25 | biostudies-arrayexpress
| S-EPMC7605160 | biostudies-literature
| S-EPMC5323132 | biostudies-literature
2020-12-26 | PXD023317 |
| S-EPMC2999923 | biostudies-literature